Study design: We evaluated the eects of serotonin (5-HT) agonists on in vitro models of spinal cord compressive injury. Evoked potentials in injured rat spinal cords (n=24) were recorded during perfusion with 5-HT agonists. Objectives: To evaluate the therapeutic eects of 5-HT agonists on the recovery of compound action potentials in injured spinal cords. Methods: Rat dorsal columns were isolated, placed in a chamber, and injured by extradural compression with a clip. Conducting action potentials were activated by supramaximal constant current electrical stimuli and recorded during perfusion with 5-HT agonists and antagonists. Results: After inducing compression injuries, mean action potential amplitudes were reduced to 33.9+5.4% of the pre-injury level. After 120 min of perfusion with Ringer's solution, the mean amplitudes recovered to 62.8+8.4% of the pre-injury level. At a concentration of 100 mM, perfusion with tandospirone (a 5-HT1A agonist) resulted in a signi®cantly greater recovery of mean action potential amplitudes at 2 h after the injury (86.2+6.9% of pre-injury value) as compared with the control Ringer's solution (62.8+8.4% of pre-injury value, P50.05). In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+11.7% of pre-injury value). 5-HT1A and 5-HT2A agonist did not consistently alter latencies of the action potentials. Conclusion: The 5-HT1A receptor agonist was eective for the recovery of spinal action potential amplitudes in a rat spinal cord injury model.
Introduction
During the acute phase of a spinal cord injury, 5-HT may accelerate secondary damage, since it is known to be released at the injury site. 1 ± 3 We recently showed that both the 5-HT1A and 5-HT2A receptor subtypes are present on spinal dorsal column axons, and that they have opposing eects on axonal excitability. 5-HT2A agonists strongly excite action potentials, whereas 5-HT1A agonists depress them. 4 ± 6 Further, mianserin (5-HT2A antagonist) has been reported to be neuroprotective in acute spinal cord injuries. 7, 8 Thus, 5-HT receptors may play a role in the pathological responses of axons to injury. However, in the absence of any previous evidence for 5-HT receptors existing on axons, most hypotheses regarding 5-HT mediated secondary axonal injury have focused on indirect mechanisms, such as posttraumatic ischemia. Our previous results provided a theoretical basis for the direct action of 5-HT mediating excitotoxicity in axons, and suggested a new and interesting therapeutic approach to spinal cord injury. We postulated that 5-HT 1A agonists depress axonal excitability and, as a consequence, they may also exert neuroprotective eects. To determine the role of 5-HT 1A agonist in acute spinal cord injury, we evaluated methods of 5-HT agonists treatment with in vitro models of dorsal column axon compressive injury.
Materials and methods
A total of 24 male adult Wistar rats weighing 250 ± 350 g were used, after being anesthetized with methoxy¯urane and decapitated. Care of the animals was conducted in accordance with the Guide to the Care and Use of Experimental Animals (Shiga University of Medical Science). The dorsal columns were isolated, 9,10 placed in a 3 ml recording chamber, and superfused at 120 ml/h with room-temperature (23 ± 278C) Ringer's solution for 2 ± 3 h to wash out the methoxy¯urane and stabilize the responses. The Ringer's solution contained NaCl (124 mM), KCl (3 mM), Na 2 HPO 4 (1 mM), NaHCO 3 (26 mM), MgSO 4 (1.5 mM), CaCl 2 (1.5 mM), and glucose (10 mM). The solution was saturated with O 2 (95%) and CO 2 (5%) at pH 7.4.
Many 5-HT receptor subtypes have been discovered in central nervous tissues and described. 11 0.92 ms in experiments using maximal stimuli. The 5-HT agonist solutions included 0.01% ascorbic acid (Sigma, St. Louis, MO, USA) to inhibit oxidation, which had no eect on the action potentials in the preparations.
At superfusion rates of 120 ml/h, we predicted that drug concentrations in the chamber would approach 95% of the concentrations in the incoming¯uid within 6 min, 99% within 10 min, and 99.9% by 30 min. We applied the agonists for 20 min. Further, the preparations were incubated for 10 min before and 10 min after injury.
To activate the action potentials, we applied 0.2 Hz constant-current 200 ms duration pulses (Pulse Generator, MacLab Software, Australia) with a bipolar platinum electrode placed on the dorsal column (Stimulator, Nihon Kohden SEM4201, Japan). Maximal response by stimulation was determined by progressively elevating the current intensity until the response no longer showed a greater amplitude with additional current. The action potentials were recorded using glass micropipettes ®lled with 1 M NaCl that were inserted 50 mm deep into the dorsal column. The mean conduction distance between the stimulus and recording electrodes was 2.3+0.54 mm. The voltage signals were ampli®ed (Ampli®er (1006), Nihon Kohden AB601G, Japan), analyzed and displayed graphically on a computer (Data Acquisition, MacLab Software, Macintosh, PowerBook550c), Figure 1 . Response amplitudes were measured from the initial positive peak (P1) to the ®rst large negative peak (N1) of each compound action potential. Response latencies were measured from stimulus onset to N1. The mean action potential amplitudes and latencies are expressed as percentages of the pre-injury control levels, which were obtained before spinal cord compression. All+values indicate standard deviations. To compare the treatment protocols, we applied statistical analysis. Signi®cant dierences between the control and treatment groups were determined by analysis of variance (ANOVA). Dierences were deemed statistically signi®cant at P50.05.
Results
The isolated rat dorsal columns were typically 3.0 cm in length. Stimulation with constant-current pulses activated robust compound action potentials that were conducted along the length of the dorsal column preparations. Table 2 summarizes the mean control amplitudes and latencies found in individual groups. Since stimulus and recording positions diered from preparation to preparation, the control response amplitudes and latencies varied. However, the response characteristics remained stable within each experiment, seldom varying more than 5% over periods of 20 ± 30 min.
After compression injury, the mean action potential amplitudes were reduced to 33.9+5.4%, and then recovered to 62.8+8.4% after 120 min of perfusion with Ringer's solution. At 10 mM and 100 mM concentrations, perfusion with tandospirone showed recovery values of 68.3+14.5% and 86.2+6.9% of the pre-injury values, respectively, and the 100 mM concentration of tandospirone resulted in a signi®-cantly greater recovery of mean action potential amplitudes as compared with the control Ringer's solution 2 h after injury (P50.05). The latency shifts with 10 mM and 100 mM concentrations of tandospirone were respectively 2.3+4.8% and 2.2+2.0%. In contrast, 100 mM of quipazine (a 5-HT 2A agonist) caused signi®cantly less recovery as compared with the control Ringer's solution from 60 to 100 min after injury (P50.05). Quipazine did not consistently aect response latencies. At a 50 mM concentration, mianserin (a 5-HT 2A antagonist) eliminated the inhibitory eects of 100 mM quipazine, whereas 5-HT did not signi®cantly aect the recovery of response amplitudes. Moreover, at 120 min after injury, neither the 10 mM nor 100 mM concentration of quipazine showed a signi®cant reduction of amplitudes, while a 50 mM concentration of mianserin had no eect on the The means and standard deviations of amplitude and latency changes are listed. The number of experiments is listed in columǹ n'. Maximal in the column entitled`Stim' indicates the dorsal columns were activated with 100% supramaximal (maximal) stimuli The percentage values indicate dierences from pre-drug application levels. The means and standard deviations of amplitude and latency changes are listed. The number of experiments is listed in column`n'. Signi®cant changes are indicated by *(P50.05) as compared to the control group (H)
change of action potentials in the in vitro preparations.
Discussion
More than three decades ago, Osterholm, et al.
12
suggested that the neurotransmitter 5-HT causes tissue damage in the brain. It has since been proposed that 5-HT contributes to the posttraumatic decline of blood ow and edema seen in injured spinal cords. 13 ± 16 Microdialysis studies have shown that a spinal cord injury releases large amounts of 5-HT into extracellular spaces, 3, 17, 18 and we also reported that 5-HT is released from neural elements at the injury site and is transiently taken up by platelets.
1,2 Mianserin, a 5-HT antagonist, has been reported to have bene®cial eects towards the recovery of neurologic and neurophysiologic functions in acute spinal cord injury models. 7, 8 However, the mechanisms by which 5-HT causes secondary tissue damage, especially with axons, are not well understood. Most investigators have focused on the possible indirect eects of 5-HT, such as posttraumatic ischemia, and it has been demonstrated that some peripheral and central axon terminals have 5-HT autoreceptors. 19, 20 We recently found that spinal axons possess 5-HT receptors and suggested that 5-HT may have a direct excitotoxic eect on spinal axons. 4 ± 6 In previous experiments, 5-HT had robust eects on dorsal columns obtained from rats, 4 ± 6 and both 5-HT1A and 5-HT2A receptor subtypes were found on spinal dorsal column axons, however, they demonstrated opposing eects on axonal excitability. Further, we found that 5-HT2A agonists strongly excite action potentials, while 5-HT1A agonists depress them. 4 ± 6 It would be of interest to extend this area of study to investigate actual injured spinal cords, as the ratio of 5-HT 2A /5-HT 1A receptor expression at various stages after injury may well in¯uence axonal responses to the extracellular neurotransmitter derangements that occur during those processes. In the previous study, it has been demonstrated that the neurotransmitters had the eects on dorsal columns obtained from neonatal rats. 4 While the sensitivity diminished with maturation of dorsal column. We thought that the damage of the myelin sheath by spinal cord injury might cause the penetration of neurotransmitter. Our Figure 2 Time course of the protocol F (100 mM tandosporine), which induced excitability changes. The ordinate indicates response amplitude as a percentage of the pre-drug control level Figure 3 The eects of (1) 100 mM quipazine (protocol C), (2) 100 mM quipazine with 50 mM mianserin (protocol D), (3) 100 mM tandosporine (protocol F) on compound action potentials in adult rat dorsal columns 11 while tandospirone is commonly used to treat anxiety disorders. 21 It has been reported that the 5-HT-induced nociceptive response is mediated by 5-HT2A receptors in the periphery. 22 Therefore, our study also suggests a therapeutic approach for the pain and numbness.
The data from this present study indicate that tandospirone and quipazine have opposing eects on an injured spinal cord, as the recovery of the compound action potential amplitude with 100 mM tandosporine signi®cantly exceeded that seen in the control group, and quipazine (100 mM) accelerated the amplitude decrease at 60 ± 100 min after injury. Moreover, mianserin (50 mM) blocked the quipazine induced amplitude change. The most conservative explanation of these results is that 5-HT 2A receptors increase the excitotoxicity of dorsal column axons while 5-HT 1A receptors decrease it following spinal cord injury. In conclusion, the 5-HT1A receptor agonist was eective for the recovery of spinal action potential amplitudes in a rat spinal cord injury model.
